Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

4D MOLECULAR THERAPEUTICS, INC.

(FDMT)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Choroideremia Pipeline: Emerging Therapies and Key pharma players involved by DelveInsight | 4D Molecular Therapeutics, Roche, Biogen and Many Others

06/08/2021 | 04:40am EST

Choroideremia(CHM) is an X-linked chorioretinal dystrophy characterized by progressive degeneration of the choroid, retinal pigment epithelium and retina. This disease is caused by mutations in the X-linked CHM gene encoding a Ras-related GTPase Rab escort protein (REP)-1, which is extremely important for the retinal function. Choroideremia is characterized by extensive loss of all retinal layers in the eyes.

DelveInsight's, "Choroideremia Pipeline Insight, 2021" report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in Choroideremia pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Request for Free Sample Report: https://www.delveinsight.com/sample-request/choroideremia-pipeline-insight

Some of Choroideremia Companies are:*4D Molecular Therapeutics *Roche *Biogen *Curative Biotechnology *And Many Others

Request for Free Sample Report: https://www.delveinsight.com/sample-request/choroideremia-pipeline-insight

DelveInsight's Choroideremia report covers around 50+ products under different phases of clinical development like*Late-stage products (Phase II and Phase II/III) *Mid-stage products (Phase II and Phase II/III) *Early-stage products (Phase I/II and Phase I) along with the details of *Pre-clinical and Discovery stage candidates *Discontinued & Inactive candidates *Route of Administration

Choroideremia Key Products*4D-110 *RG 6367 *BIIB111 *Metformin *And Many Others

Request for Free Sample Report: https://www.delveinsight.com/sample-request/choroideremia-pipeline-insight

Current Choroideremia Treatment Scenario and Choroideremia Emerging Therapies:*How many companies are developing Choroideremia drugs? *How many Choroideremia drugs are developed by each company? *How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Choroideremia? *What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Choroideremia therapeutics? *What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies? *What are the clinical studies going on for Choroideremia and their status? *What are the key designations that have been granted to the emerging drugs?

Request for Free Sample Report: https://www.delveinsight.com/sample-request/choroideremia-pipeline-insight

Table of Contents:

Introduction

Executive Summary

Choroideremia: Overview

Pipeline Therapeutics

* Comparative Analysis

Therapeutic Assessment

Choroideremia - DelveInsight's Analytical Perspective

In-depth Commercial Assessment

Choroideremia Collaboration Deals

Late Stage Products (Phase III)

* Comparative Analysis

BIIB111: Biogen

Drug profiles in the detailed report.....

Early Stage Products (Phase I)

* Comparative Analysis

4D110: 4D Molecular therapeutics

Drug profiles in the detailed report.....

Preclinical stage products

* Comparative Analysis

Metformin: Curative Biotechnology

Drug profiles in the detailed report.....

Inactive Products

* Comparative Analysis

Choroideremia Key Companies

Choroideremia Key Products

Choroideremia- Unmet Needs

Choroideremia- Market Drivers and Barriers

Choroideremia- Future Perspectives and Conclusion

Choroideremia Analyst Views

Choroideremia Key Companies

Appendix

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing end-to-end comprehensive solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.

Media Contact

Company Name: DelveInsight Business Research LLP

Contact Person: Ankit Nigam

Email: info@delveinsight.com

Phone: +19193216187

Address:304 S. Jones Blvd #2432

City: Albany

State: New York

Country: United States

Website: https://www.delveinsight.com/report-store/choroideremia-pipeline-insight

Source: www.abnewswire.com

.

(C) 2021 M2 COMMUNICATIONS, source M2 PressWIRE

Stocks mentioned in the article
ChangeLast1st jan.
4D MOLECULAR THERAPEUTICS, INC. -4.29% 14.28 Delayed Quote.-34.91%
CURATIVE BIOTECHNOLOGY, INC. 3.45% 0.06 Delayed Quote.11.11%
ROCHE HOLDING AG -1.22% 360.65 Delayed Quote.-4.87%
All news about 4D MOLECULAR THERAPEUTICS, INC.
01/14BofA Securities Says IPO Performance Was Weak in 2021 But Fundamentals Remain Intact fo..
MT
01/114D MOLECULAR THERAPEUTICS INC. : Regulation FD Disclosure, Financial Statements and Exhibi..
AQ
01/104D Molecular Therapeutics' Treatment for Retinal Disorder Gets FDA Fast Track Designati..
MT
01/104D Molecular Therapeutics Gets Fast-Track Designation for Retinal Disease Treatment
DJ
01/104D Molecular Therapeutics Announces FDA Fast Track Designation Granted to 4D-125 for th..
AQ
01/104D Molecular Therapeutics Announces FDA Fast Track Designation Granted to 4D-125 for th..
CI
01/064D Molecular Says First Patient Dosed in Trial of 4D-150 Candidate to Treat Eye Disease
MT
01/064D Molecular Therapeutics Announces First Patient Dosed in Phase 1/2 Clinical Trial of ..
GL
01/064D Molecular Therapeutics Announces First Patient Dosed in Phase 1/2 Clinical Trial of ..
GL
01/064D Molecular Therapeutics Announces First Patient Dosed in Phase 1/2 Clinical Trial of ..
CI
More news
Analyst Recommendations on 4D MOLECULAR THERAPEUTICS, INC.
More recommendations
Financials (USD)
Sales 2021 18,8 M - -
Net income 2021 -71,7 M - -
Net cash 2021 318 M - -
P/E ratio 2021 -5,56x
Yield 2021 -
Capitalization 459 M 459 M -
EV / Sales 2021 7,50x
EV / Sales 2022 43,7x
Nbr of Employees 121
Free-Float 90,4%
Chart 4D MOLECULAR THERAPEUTICS, INC.
Duration : Period :
4D Molecular Therapeutics, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends 4D MOLECULAR THERAPEUTICS, INC.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 4
Last Close Price 14,28 $
Average target price 45,25 $
Spread / Average Target 217%
EPS Revisions
Managers and Directors
David H. Kirn President, Chief Executive Officer & Director
August J. Moretti Chief Financial Officer
John F. Milligan Executive Chairman
Melissa Kotterman Vice President-Discovery & Engineering
Fred Kamal Chief Technical Officer
Sector and Competitors
1st jan.Capi. (M$)
4D MOLECULAR THERAPEUTICS, INC.-34.91%459
MODERNA, INC.-36.98%64 900
LONZA GROUP AG-15.65%52 307
IQVIA HOLDINGS INC.-14.60%46 031
SEAGEN INC.-17.50%23 323
ICON PUBLIC LIMITED COMPANY-18.65%20 508